Article

PSA doubling time: Solid predictor of PCa survival

New Orleans--PSA doubling time (PSADT) appears to be a strong predictor of the probability of distant metastasis and prostate cancer-specific survival in men with biochemical relapse after radical prostatectomy, according to Mario A. Eisenberger, MD.

Related Videos
3d rendered illustration - bladder | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Related Content
Prostate Gland - (BPH) Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
December 26th 2024

Top 10 BPH articles and videos of 2024

Benjamin P. Saylor
As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
3d rendered genetic illustration of human dna under microscope created with generative ai technology | Image Credit: © Picture Studio - stock.adobe.com
December 24th 2024

Quiz: CUA guidelines on specimen and timing considerations with genetic testing

Patrick Campbell
Test your knowledge of these often-overlooked but essential aspects of genetic and genomic testing.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
FDA approves vibegron for OAB symptoms in pharmacologically treated BPH
December 23rd 2024

FDA approves vibegron for OAB symptoms in pharmacologically treated BPH

Hannah Clarke
The approval of vibegron is supported by data from the phase 3 COURAGE trial.
Navigating work-life balance: VUMC’s Family Planning for Surgeons Series
December 23rd 2024

Navigating work-life balance: VUMC’s Family Planning for Surgeons Series

Lauren E. Corona, MD
"I hope that [attendees] will be exposed to a community where they feel that they're able to freely ask questions, gain accurate information, and feel heard, validated, and connected," says Lauren E. Corona, MD.
© 2024 MJH Life Sciences

All rights reserved.